Navigation Links
Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting

SAN FRANCISCO, May 21 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that additional clinical results from a Phase 1-2 clinical trial involving 140 men with advanced prostate cancer evaluating MDV3100, a next-generation androgen receptor antagonist, will be presented in an oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla.

    Oral Abstract Session:      Genitourinary (Prostate) Cancer

    Abstract Title:            "Antitumor Activity of MDV3100 in a Phase 1-2
                               Study of Castration-Resistant Prostate Cancer
                               (CRPC)" (Abstract #5011)

    Presentation Date/Time:     Saturday, May 30, at 4:15 p.m. ET

    Presenter:                  Dr. Howard Scher, principal investigator,
                                chief of the Genitourinary Oncology Service
                                and the D. Wayne Calloway Chair in Urologic
                                Oncology at Memorial Sloan-Kettering Cancer
                                Center in New York

    Location:                   Level 3, Chapin Theater W320

Additionally, this abstract was selected by ASCO for inclusion in the Best of ASCO(R) program, an educational initiative covering highlights from the ASCO Annual Meeting to increase global access to cutting-edge science.

Medivation recently received written permission from the U.S. Food and Drug Administration to begin a pivotal Phase 3 trial of MDV3100 in patients with advanced prostate cancer. The primary endpoint of the trial will be overall survival.

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer.(i) In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The Dimebon program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at

(i) American Cancer Society

    Medivation, Inc.                                WeissComm Partners
    Patrick Machado, Chief Financial Officer        Lee-Ann Murphy
    (415) 829-4101                                  (415) 946-1088

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
2. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
3. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
4. Medivation Announces Participation in Upcoming Conferences
5. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
8. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
9. Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
10. Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update
11. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology: